The Evolving Role of Immunotherapy in the Treatment of Genitourinary Cancers: An Update for Pharmacists

This educational activity is sponsored by Postgraduate Healthcare Education, LLC (PHE) and supported by an educational grant from Merck & Company, Inc.

FACULTY

Kirollos S. Hanna, PharmD, BCPS, BCOP
Oncology Pharmacy Manager
M Health Fairview - Maple Grove
Assistant Professor of Pharmacy
Mayo Clinic College of Medicine
Rochester, Minnesota

FINANCIAL DISCLOSURE

Dr. Hanna has disclosed that he has served as a paid consultant for Seagen, Abbvie, Rigel, AstraZeneca, Bristol Myers Squibb, BeiGene, and Astellas; and has received fees for other non-CE services from Seagen, BeiGene, Bristol Myers Squibb, and Astellas.

The clinical reviewer Lisa Holle, PharmD, BCOP, FHOPA, has disclosed that she has served as a consultant for McGraw Hill Education and Postgraduate Healthcare Education LLC; conducted research for the International Society of Oncology Pharmacy Practitioners; and has received honoraria for CE programs from AXIS Medical Education, Hematology/Oncology Pharmacy Association, HMP CME, Pharmacy Times Continuing Education, and Postgraduate Healthcare Education LLC.

Susanne Batesko, RN, BSN, Robin Soboti, R.Ph, and Susan R. Grady, MSN, RN, as well as the planners, managers, and other individuals, not previously disclosed, who are in a position to control the content of Postgraduate Healthcare Education (PHE) continuing education (CE) activities hereby state that they have no relevant conflicts of interest and no financial relationships or relationships to products or devices during the past 12 months to disclose in relation to this activity. PHE is committed to providing participants with a quality learning experience and to improve clinical outcomes without promoting the financial interests of a proprietary business.

ACCREDITATION STATEMENTS

PHARMACY
acpePostgraduate Healthcare Education, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
UAN: 0430-0000-21-060-H01-P
Credits: 2.0 hours (0.20 ceu)

Type of Activity: Application
Media: Internet

Fee Information: There is no fee for this educational activity
Estimated time to complete activity: 120 minutes

Published

September 20, 2021

Expires

March 20, 2022

TARGET AUDIENCE

This accredited activity has been designed for oncology, managed care and specialty pharmacists.

HOW TO OBTAIN CREDIT

During the period September 20, 2021 to March 20, 2022, participants must 1) read the learning objectives and faculty disclosures; 2) view the educational activity; and 3) complete the post-test and evaluation form directly after the activity within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.

Goal

To provide oncology, managed care, and specialty pharmacists with advanced knowledge about optimal and emerging immune-oncology treatment options for adult patients with genitourinary cancers, such that they can optimize patient care.

LEARING OBJECTIVES

Upon completion of this program, participants should be better able to:

  • Discuss current and emerging immune checkpoint inhibitor (ICI) use in genitourinary cancer treatment alone and in combination regimens
  • Identify challenges to and best practices for ICI use in genitourinary cancer treatment
  • Demonstrate approaches to effectively recognize and manage immune-related adverse events of immunotherapies alone and in combination regimens for genitourinary cancer treatment

REQUIRED COMPUTER HARDWARE/SOFTWARE

Please ensure the computer system you plan to use meets the following minimum requirements:

  • Operating System: Windows 98 or higher & Macintosh 2.2 or higher
  • Internet Browser (Mac & Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher, & Opera 5 or higher
  • Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible
  • Peripherals: Computer speakers or headphones
  • Monitor Screen Resolution: 320 x 480 or higher
  • Media Viewing Requirements: Adobe Reader, Microsoft PowerPoint, Flash Player & HTML5

Disclosure of Unlabeled Use and Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Postgraduate Healthcare Education, LLC or Merck & Company, Inc. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, and possible contraindications on dangers in use, (review of any applicable manufacturer's product information) and comparison with recommendations of other authorities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that all information contained herein is accurate in accordance with the latest available scientific knowledge at the time of acceptance for publication. However, because information regarding drugs (their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions, etc.) is subject to constant change, the reader is advised to check the manufacturer's package insert for information concerning recommended dosages and potential problems and cautions prior to dispensing or administering the drug. Special precautions should be taken when a drug is new, or highly toxic, or is unfamiliar to the dispenser or administrant. This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration (FDA). Neither the publisher nor sponsor promotes the use of any agent outside of approved labeling. Statements made in this monograph have not been evaluated by the FDA.